Loading
A phase 2/3 trial of Abemaciclib, Abiraterone acetate, Prednisone in prostate cancer, run by Eli Lilly and Company, active and no longer recruiting.
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer is a phase 2/3 interventional study registered as NCT03706365 by Eli Lilly and Company, with 393 participants enrolled, started 2018-11-26 and due to reach its primary completion in 2024-01-02. Interventions recorded: Abemaciclib, Placebo, Abiraterone acetate, Prednisone. Conditions listed: Prostate Cancer. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
393 enrolled.
95% CI 19.33 to 27.48; Figures from the ClinicalTrials.gov results section (first posted 2025-03-06), not from a publication · 95% CI 16.47 to 24.36
Source95% CI 30.58 to 46.65; Figures from the ClinicalTrials.gov results section (first posted 2025-03-06), not from a publication · 95% CI 29.52 to NA
Source95% CI 34.6 to 55.9; Figures from the ClinicalTrials.gov results section (first posted 2025-03-06), not from a publication · 95% CI 43.4 to 66.2
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Radiographic Progression Free Survival (rPFS)primary | Abemaciclib | 206 | 21.96 months | 0.829 (0.619 to 1.111) | 0.2123 | link |
| Placebo | 187 | 20.28 months | ||||
| Overall Survival (OS) | Abemaciclib | 206 | 38.01 months | 0.927 (0.669 to 1.285) | 0.6507 | link |
| Placebo | 187 | 33.21 months | ||||
| Objective Response Rate (ORR): Percentage of Participants With a Complete Response (CR) or Partial Response (PR) | Abemaciclib | 84 | 45.2% | - | - | link |
| Placebo | 73 | 54.8% |
Shares Abemaciclib, Eli Lilly (incl. Loxo), CDK4/6 inhibitors, Prednisone.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prednisone, Metastatic castration-resistant prostate cancer.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prednisone, Metastatic castration-resistant prostate cancer.
Shares Abiraterone acetate, Prednisone, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Abemaciclib, Eli Lilly (incl. Loxo), CDK4/6 inhibitors.
Shares Abemaciclib, Eli Lilly (incl. Loxo), CDK4/6 inhibitors.